SeaBridge Investment Advisors LLC Decreases Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

SeaBridge Investment Advisors LLC reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 12,260 shares of the medical research company’s stock after selling 145 shares during the period. SeaBridge Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $3,571,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of TMO. Private Trust Co. NA lifted its holdings in shares of Thermo Fisher Scientific by 66.7% in the 2nd quarter. Private Trust Co. NA now owns 3,273 shares of the medical research company’s stock valued at $961,000 after purchasing an additional 1,310 shares during the last quarter. Fulton Bank N.A. lifted its holdings in shares of Thermo Fisher Scientific by 2.6% in the 2nd quarter. Fulton Bank N.A. now owns 4,423 shares of the medical research company’s stock valued at $1,299,000 after purchasing an additional 110 shares during the last quarter. Swedbank lifted its holdings in shares of Thermo Fisher Scientific by 91.8% in the 2nd quarter. Swedbank now owns 782,855 shares of the medical research company’s stock valued at $229,909,000 after purchasing an additional 374,739 shares during the last quarter. Davis Rea LTD. purchased a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $1,443,000. Finally, Carroll Financial Associates Inc. lifted its holdings in shares of Thermo Fisher Scientific by 9.4% in the 2nd quarter. Carroll Financial Associates Inc. now owns 1,367 shares of the medical research company’s stock valued at $401,000 after purchasing an additional 118 shares during the last quarter. 88.21% of the stock is owned by institutional investors and hedge funds.

TMO stock traded up $0.10 during trading on Tuesday, hitting $283.64. The company had a trading volume of 19,292 shares, compared to its average volume of 1,644,845. The firm has a market cap of $112.70 billion, a PE ratio of 25.53, a price-to-earnings-growth ratio of 1.84 and a beta of 1.13. Thermo Fisher Scientific Inc. has a 1-year low of $208.34 and a 1-year high of $305.45. The firm has a 50-day moving average price of $288.43 and a 200-day moving average price of $281.41. The company has a quick ratio of 1.07, a current ratio of 1.49 and a debt-to-equity ratio of 0.58.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.01 by $0.03. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. The firm had revenue of $6.32 billion for the quarter, compared to analysts’ expectations of $6.31 billion. During the same quarter in the previous year, the firm posted $2.75 EPS. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 12.25 earnings per share for the current year.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 2,271 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $298.00, for a total transaction of $676,758.00. Following the transaction, the chief executive officer now owns 283,502 shares in the company, valued at approximately $84,483,596. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $284.83, for a total value of $14,241,500.00. Following the transaction, the chief executive officer now owns 342,193 shares in the company, valued at approximately $97,466,832.19. The disclosure for this sale can be found here. Insiders have sold a total of 54,104 shares of company stock worth $15,418,539 in the last quarter. 0.45% of the stock is currently owned by insiders.

Several analysts have recently weighed in on TMO shares. Needham & Company LLC boosted their target price on Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a report on Thursday, July 25th. ValuEngine cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Barclays set a $330.00 price target on Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Monday, July 15th. Finally, Credit Suisse Group restated a “buy” rating and issued a $310.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday, July 31st. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $305.27.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: Bollinger Bands

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit